[ad_1]
Nasdaq-listed mainland China anti-cancer drug research and development company, Baiji Shenzhou (06160), will raise funds for the future, raising up to $ 7.32 billion yuan, whose entry is scheduled for August 8.
The first right of entry for the students of the Department of Health (01672) was higher than the entrance fee of more than 16,000 yuan, and the price of Baiji was also 113,000 yuan. Liang Heng, chief financial officer and head of unit strategy, explained that Baekje being listed on NASDAQ, prices should refer to the price of the stock, and 100 shares per lot is the minimum requirement, so admission fees are not expensive.
The stock was increased in several rounds after registration in the United States. It is asked how long it will take to refinance after the IPO. Liang Heng said that 75% of the Fundraising will be used for clinical research drug zanubrutinib BTK and PD-1 tislelizumab. Test and sign up for registration, and establish a marketing team. He said the company has sufficient liquidity, as well as IPO fund-raising revenue, and the number is considerable, which can support short-term demand. John Olyer, founder of Baekje China, said that many investors around the world know biotechnology, but do not know the Chinese market. Chinese investors are familiar with the Chinese market, but do not know biotechnology, so he thinks the company is Nasdaq. In addition to establishing a brand in the Asian region, it can also educate international and Chinese investors.
Oyler is excited to see new anti-cancer drugs peer-to-peer, related to "the common enemy is cancer," and the goal of pharmaceutical companies is to develop new affordable drugs: the cancer population is large and it is impossible to rely solely on a company. Do it.
The co-sponsors of Baekje China are Morgan Stanley and Goldman Sachs.
For more information on IPO and fund-raising data badysis, please visit the new Hong Kong Stocks 360 IPO page.
[ad_2]
Source link
